Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: The bulk of the money will come from Teva Pharmaceutical Industries Ltd. and its affiliates for paying to delay a generic narcolepsy drug, Provigil, from entering the market for nearly six years. Teva is paying $69 million, which Becerra says is the largest pay-for-delay settlement received by any state. Such agreements let the developer of brand name drugs keep their monopolies over the drugs after their patents expire, thereby letting them continue to charge consumers higher prices. The drug developer pays the generic manufacturer to keep the cheaper version of the drug from entering the marketplace for an agreed period of time. Teva said the money will come from a pre-existing fund that was created in 2015 as part of the company’s settlement with the U.S. Federal Trade Commission over similar claims, and it will not make any additional payments. Becerra said such agreements can force consumers and the health care market to pay as much as 90% more than if there were generic alternatives. More than $25 million of the settlement will go to a consumer fund for California residents who purchased Provigil, Nuvigil or Modafinil between 2006 and 2012. “No one in America should be forced to skip or ration doses of medicine that they need ... and certainly not because a drug company is colluding to keep the price of your drug artificially high even when cheaper options could be available. But that’s what’s happening,” Becerra said. The second, $760,000 settlement is with Teva, Endo Pharmaceuticals and Teikoku Pharma USA over keeping a genetic alternative to the pain patch Lidoderm from entering the market for nearly two years. Teva said it is paying $200,000 to cover the state’s legal costs after settling similar federal claims earlier this year. Neither Endo nor Teikoku responded to requests for comment. Both settlements bar the companies from pay-for-delay agreements for several years. Teva is agreeing to not to enter any such agreements for 10 years, while Endo Pharmaceuticals has an eight-year agreement and Teikoku a 20-year injunction. Teva said the restriction is identical to its federal consent decree. Becerra also backed pending legislation, AB824 by Democratic Assemblyman Jim Wood of Santa Rosa, that would ban such agreements. The measure would require pharmaceutical companies to prove that their agreements are not anticompetitive. It passed the Assembly 56-0 in May and is awaiting a vote in the Senate. Pharmaceutical companies oppose the bill, arguing the Federal Trade Commission already does this monitoring. ___ This story has been corrected to say that while there are four settlement agreements, they involve only three companies. Claim: 3 companies pay California $70 million for delaying drugs.

Answer: Three pharmaceutical companies collectively are agreeing to pay California nearly $70 million to settle allegations that they delayed drugs to keep prices high, California Attorney General Xavier Becerra said Monday.


Question: Paragraph: The Sackler family owns Purdue Pharma, the privately held drug company that has made billions from OxyContin, and Sacklers hold most of the seats on the board. Members of the family have been accused in a case brought by the state of Massachusetts of deceiving patients and doctors about the drug’s risks as deaths mounted. And documents recently released in the case shine new light on former Purdue Pharma President Richard Sackler’s role in the aggressive marketing of the powerful opioid. As the allegations mount, family members who made their fortunes well before OxyContin even went on the market have sought to distance themselves from their relatives. At the same time, activists have called on institutions to cut ties with the Sacklers, staging protests at museums that have received millions in donations. “The Sackler name is becoming synonymous with the opioid epidemic, and it is damning for these institutions to have their name up,” said Nan Goldin, a photographer whose works have been displayed at Harvard’s Arthur M. Sackler Museum and at New York’s Metropolitan Museum of Art, which has a Sackler Wing. Lost in the outrage: One of the most generous and best known of the Sacklers died in 1987, nearly a decade before OxyContin was released. Arthur M. Sackler made his money from medical research, medical advertising and trade publications. His younger brothers, Raymond and Mortimer, bought out his stake after he died. Arthur Sackler’s name is on a gallery at the Smithsonian, a wing of galleries at London’s Royal Academy of Arts and a museum at Beijing’s Peking University. The Sackler Wing at the Met, which houses the celebrated Temple of Dendur from ancient Egypt, was funded by all three brothers. Richard has likewise donated heavily to various institutions. After a federal investigation, Purdue Pharma and three executives — none of them Sacklers — pleaded guilty in 2007 and agreed to pay more than $600 million for misleading the public about the risks of OxyContin. The Stamford, Connecticut, company has also been hit with a multitude of lawsuits over its role in the opioid crisis that killed more than 47,000 people in 2017 alone. Arthur’s nephew, Richard Sackler, who became president of Purdue Pharma in 1999 and remains on the board, is at the center of the litigation. He and other current and former executives have been accused of hiding the dangers of the drug from doctors and patients, encouraging physicians to prescribe more of the highest doses and minimizing the abuse crisis as it was unfolding. “This is not too bad. It could have been far worse,” he wrote to Purdue Pharma executives in 2001 after a federal prosecutor reported that 59 people in one state had died from OxyContin, according to documents released this week in the Massachusetts case. At the launch party for OxyContin in 1996, Richard Sackler boasted the drug would bring a “blizzard of prescriptions that will bury the competition,” the documents say. Years later, they say, he sought to shift blame onto drug users themselves, recommending the company “hammer on the abusers in every way possible.” “Richard followed that strategy for the rest of his career: collect millions from selling addictive drugs, and blame the terrible consequences on the people who became addicted,” attorneys in Massachusetts Attorney General Maura Healey’s office wrote. “By their misconduct, the Sacklers have hammered Massachusetts families in every way possible. And the stigma they used as a weapon made the crisis worse.” A spokesman for Richard Sackler’s family referred questions about the lawsuit to the company. Purdue Pharma said in a statement that Massachusetts’ case — the first one brought by a state to personally name members of the Sackler family — is “littered with biased and inaccurate characterizations.” The company said it will “aggressively defend against these misleading allegations.” Arthur Sackler’s widow and children insist that they never financially benefited from the sale of OxyContin. “It is a gross injustice to connect Arthur to the opioid crisis some 30 years after his death when he had nothing to do with it,” Dame Jillian Sackler said in a statement. “It denies the many important contributions he made working to improve world health and to build cultural bridges between peoples.” But activists have made no distinction between Arthur and his relatives. In July, dozens of activists led by Goldin held a protest inside the Arthur M. Sackler Museum at Harvard, scattering pill bottles and holding banners that read “SHAME ON SACKLER.” Similar demonstrations have been held at the Met and the Smithsonian. Goldin, who was addicted OxyContin for years, said that getting the institutions to act will be difficult. “Who is going to turn down the money? They offer millions to these institutions, and the board members are not necessarily committed to action, so it’s going to take a lot,” she said. A Met spokesman said that the Sackler family’s support began decades before the opioid crisis, but that the museum will be examining its gift acceptance policies. The Guggenheim, home to the Sackler Center for Arts Education, had no comment. A Harvard spokesman said in an email that Arthur Sackler’s donation in 1982 paid for the construction of the building that originally housed the museum but that his foundation does not fund the museum. ___ Associated Press reporter Verena Dobnik contributed to this report from New York. ___ Follow Alanna Durkin Richer at http://www.twitter.com/aedurkinricher Claim: Opioid crisis brings unwanted attention to wealthy family.

Answer: The Sackler name is emblazoned on the walls at some of the world’s great museums and universities, including the Smithsonian, the Guggenheim and Harvard. But now the family’s ties to OxyContin and the painkiller’s role in the deadly opioid crisis are bringing the Sacklers a new and unwanted kind of attention and complicating their philanthropic legacy.


Question: Paragraph: There will be 50,000 more nurses going into the NHS. The government has committed to do this by 2024/25. Not all of these nurses will be ‘new’. The government have announced the end of hospital parking charges for patients. In December it was announced that hospitals in England will have to provide free car parking to frequent hospital visitors, blue badge holders and at certain times to staff and parents of child patients. The government will build 40 new hospitals. Six hospitals in England are getting the money to upgrade their buildings within the next five years. Up to 38 hospitals are getting money to develop plans for their hospitals between 2025 and 2030, but not to actually begin any building work. The government is putting 20,000 more police on the streets. The government has committed to do this. If this happens it will take the number of police in England and Wales to almost, but not quite the same level as it was at in 2010. The government gave the police much more use of Tasers to help deal with street crime. The Home Office announced police in England and Wales can bid for part of a fund to equip their force with more Tasers. Final funding allocations will be announced in February. The government are lifting the living wage by the biggest ever amount, up to £8.72, and it will go up to £10.50. The national living wage set by the government is set to rise to £8.72 in April, the largest rise since it was put in place in 2016. It was also announced at last year’s Conservative party conference that it would rise to £10.50 within the next five years. Claim 1 of 7 Claim: The government is putting 20,000 more police on the streets.

Answer:
The government has committed to do this. If this happens it will take the number of police in England and Wales to almost, but not quite the same level as it was at in 2010.